NP10679: A new horizon for neuroprotection in aneurysmal subarachnoid hemorrhage
- 20 January 2025
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 392 (3) , 103390
Abstract
No abstract availableFunding Information
- Weill Cornell Medicine
This publication has 26 references indexed in Scilit:
- Beyond nimodipine: advanced neuroprotection strategies for aneurysmal subarachnoid hemorrhage vasospasm and delayed cerebral ischemiaNeurosurgical Review, 2024
- Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid HemorrhageNeurocritical Care, 2023
- Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective N‐methyl‐d‐aspartate Receptor InhibitorClinical Pharmacology in Drug Development, 2023
- A comprehensive description of GluN2B-selective N-methyl-D-aspartate (NMDA) receptor antagonistsEuropean Journal of Medicinal Chemistry, 2020
- NMDARs in Cell Survival and Death: Implications in Stroke Pathogenesis and TreatmentTrends in Molecular Medicine, 2020
- Poor Utilization of Nimodipine in Aneurysmal Subarachnoid HemorrhageJournal of Stroke and Cerebrovascular Diseases, 2019
- Spontaneous subarachnoid haemorrhageThe Lancet, 2017
- Excitotoxicity and stroke: Identifying novel targets for neuroprotectionProgress in Neurobiology, 2014
- Influence of GluN2 subunit identity on NMDA receptor functionNeuropharmacology, 2013
- 1,026 Experimental treatments in acute strokeAnnals of Neurology, 2006